ES2560902A2 - Método para la determinación de la intensidad de la modificación de la potencia de un medicamento - Google Patents

Método para la determinación de la intensidad de la modificación de la potencia de un medicamento Download PDF

Info

Publication number
ES2560902A2
ES2560902A2 ES201590110A ES201590110A ES2560902A2 ES 2560902 A2 ES2560902 A2 ES 2560902A2 ES 201590110 A ES201590110 A ES 201590110A ES 201590110 A ES201590110 A ES 201590110A ES 2560902 A2 ES2560902 A2 ES 2560902A2
Authority
ES
Spain
Prior art keywords
activated
potentiated
therapeutic
component
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES201590110A
Other languages
English (en)
Other versions
ES2560902R1 (es
Inventor
Oleg Iliich Epshtein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of ES2560902A2 publication Critical patent/ES2560902A2/es
Publication of ES2560902R1 publication Critical patent/ES2560902R1/es
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método para la determinación de la intensidad de la modificación de la potencia de un medicamento. La invención comprende un método para la determinación del grado de potencia modificada de un medicamento que comprende un componente terapéutico y un componente homeopático activado-potenciado, donde el componente activado-potenciado tiene algún efecto físico, químico o biológico sobre el componente terapéutico y/o la eficacia farmacológica del mismo. El componente terapéutico está biológicamente relacionado con la sustancia de partida del componente homeopático. Una medición analítica de al menos un parámetro característico de la forma terapéutica se realiza antes de su interacción con la forma activada-potenciada; la(s) misma(s) medición(es) analítica(s) se llevan a cabo después de la interacción entre las formas terapéutica y activada-potenciada. Estas mediciones sirven para cuantificar el grado de potencia modificadora asociada con la forma activada-potenciada en unidades relativas adimensionales de actividad (actividad de liberación).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25

Claims (1)

  1. imagen1
    imagen2
ES201590110A 2013-03-18 2014-03-18 Método para la determinación de la intensidad de la modificación de la potencia de un medicamento Pending ES2560902R1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013111962 2013-03-18
RU2013111962/15A RU2013111962A (ru) 2013-03-18 2013-03-18 Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Publications (2)

Publication Number Publication Date
ES2560902A2 true ES2560902A2 (es) 2016-02-23
ES2560902R1 ES2560902R1 (es) 2016-03-31

Family

ID=51211813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201590110A Pending ES2560902R1 (es) 2013-03-18 2014-03-18 Método para la determinación de la intensidad de la modificación de la potencia de un medicamento

Country Status (14)

Country Link
US (1) US9945798B2 (es)
EP (1) EP2976648A2 (es)
JP (1) JP2016512893A (es)
CN (1) CN105264383A (es)
AU (1) AU2014242599A1 (es)
CA (1) CA2907478A1 (es)
DE (1) DE112014001508T5 (es)
EA (1) EA032090B1 (es)
ES (1) ES2560902R1 (es)
GB (1) GB2531930A (es)
MX (1) MX2015013377A (es)
RU (1) RU2013111962A (es)
UA (1) UA117925C2 (es)
WO (1) WO2014155206A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040190975A1 (en) 2003-02-07 2004-09-30 Closure Medical Corporation Applicators, dispensers and methods for dispensing and applying adhesive material

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ284214A (en) * 1994-03-31 1997-07-27 Biomed Comm Inc Extreme dilutions of growth factors, homeopathic compositions, radiotherapy.
HUP9901890A3 (en) * 1996-02-12 2001-04-28 Epshtein Oleg Iliich Medicament and method of treating an organism with medicaments
RU2112976C1 (ru) 1997-04-07 1998-06-10 Акционерное общество закрытого типа "Международный концерн "ЭДАС" Способ определения качества гомеопатических лекарственных средств и устройство для его реализации
EP1045250A1 (en) * 1999-04-12 2000-10-18 INSTRUMENTATION LABORATORY S.p.A. A global test for evaluating the functionality of the thrombin/antithrombin system
RU2161955C1 (ru) 1999-07-16 2001-01-20 Эпштейн Олег Ильич Способ изменения физико-химических или физико-химических и биологических свойств вещества
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2195648C2 (ru) * 2000-11-03 2002-12-27 Эпштейн Олег Ильич Способ качественного определения гомеопатического лекарственного препарата или потенцированной формы вещества
RU2192888C1 (ru) 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
RU2191601C1 (ru) 2001-04-18 2002-10-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эректильных дисфункций
RU2181890C1 (ru) 2001-06-06 2002-04-27 Научно-исследовательский и учебно-методический центр биомедицинских технологий ВИЛАР Способ выявления веществ, обладающих адаптогенными свойствами, in vitro
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76640C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2253478C1 (ru) 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
BRPI0712540A2 (pt) 2006-06-06 2012-10-16 Oleg Iliich Epshtein agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose
RU2332236C1 (ru) 2007-02-02 2008-08-27 Олег Ильич Эпштейн Лекарственное средство для лечения гриппа у птиц
US20110135747A1 (en) * 2008-08-29 2011-06-09 Nancy Josephine Polich Homeopathic therapeutic method
AU2009301580B2 (en) * 2008-10-06 2015-11-26 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
US20130189707A1 (en) 2010-01-26 2013-07-25 Svetlana Alexandrovna Sergeeva Method of determination of autoantibody level by means of enzyme immunoassay
US8969005B2 (en) * 2010-03-28 2015-03-03 The Trustees Of The University Of Pennsylvania Gene targets associated with amyotrophic lateral sclerosis and methods of use thereof
WO2011149917A1 (en) * 2010-05-25 2011-12-01 Adlyfe, Inc. STABILIZED AMYLOID- β OLIGOMERS AND USES THEREOF
PH12013500107A1 (en) * 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
AU2011278039B2 (en) 2010-07-15 2015-07-23 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
EP2593477A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
JP2013532181A (ja) 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び胃腸管の機能的な疾患又は状態を治療する方法
DE112011102350T5 (de) 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
PH12013500142A1 (en) 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
EA029199B1 (ru) 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
KR20180127515A (ko) 2010-07-21 2018-11-28 올레그 일리치 엡쉬테인 당뇨병 및 대사성 장애의 치료를 위한 제약학적 복합 조성물 및 방법들
JP2013536174A (ja) 2010-07-21 2013-09-19 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物並びに回転性めまい、動揺病及び自律神経血管ジストニアを治療する方法
US20120258146A1 (en) 2010-07-21 2012-10-11 Oleg Iliich Epshtein Method of treating organic diseases of nervous system, pschoorganic syndrome and encephalopathy
EA029399B1 (ru) 2010-07-21 2018-03-30 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2535033C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2517084C2 (ru) 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
RU2535034C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
WO2012017328A2 (en) 2010-08-06 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
US20120263725A1 (en) 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
US20130171161A1 (en) 2010-12-23 2013-07-04 Oleg Iliich Epshtein Method and composition for the treatment of diseases caused by or associated with hiv
CN103460049B (zh) * 2011-01-18 2016-08-17 美国政府(由卫生和人类服务部的部长所代表) 扩增和检测朊病毒的方法
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Also Published As

Publication number Publication date
WO2014155206A3 (en) 2015-01-22
GB2531930A (en) 2016-05-04
UA117925C2 (uk) 2018-10-25
US9945798B2 (en) 2018-04-17
EA032090B1 (ru) 2019-04-30
CN105264383A (zh) 2016-01-20
EP2976648A2 (en) 2016-01-27
CA2907478A1 (en) 2014-10-02
RU2013111962A (ru) 2014-09-27
WO2014155206A9 (en) 2014-11-27
WO2014155206A2 (en) 2014-10-02
JP2016512893A (ja) 2016-05-09
DE112014001508T5 (de) 2016-05-19
GB201518062D0 (en) 2015-11-25
MX2015013377A (es) 2016-01-08
EA201500925A1 (ru) 2016-04-29
ES2560902R1 (es) 2016-03-31
US20140287448A1 (en) 2014-09-25
AU2014242599A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
Petrie et al. Fate of drugs during wastewater treatment
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
EP3362060A4 (en) BIOMARKERS FOR DIABETES AND TREATMENT OF DIABETES-BASED ILLNESSES
MX383494B (es) Ácidos nucleicos libres de células para el análisis del microbioma humano y componentes del mismo.
BR112016006188A2 (pt) método de tratamento com um protocolo de fármaco e um sistema com uma base de dados relacional acoplado a um ou mais dispositivos eletrônicos ; sistema para a gestão de um tratamento medicamentoso pela administração de um fármaco a um paciente e método de gestão de um tratamento com drogas usando um sistema de informação com uma base de dados relacional.
MX386251B (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
ES2543957T3 (es) Nueva composición farmacéutica para el tratamiento de infecciones fúngicas
GB2531169A (en) Method for determining degree of modified potency of bipathic medicament
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
MX390157B (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
EP3450977A4 (en) BLOOD COAGULATION DATA MEASURING APPARATUS, AND METHOD OF USE, CONNECTING ELEMENT AND SUPPORT THEREOF
KR102097856B9 (ko) 나노구조를 활용한 혈당센서용 니들어레이 및 무통 혈당센서, 이의 제조방법
ES2577405T3 (es) Composiciones para el tratamiento de úlceras periféricas de varios orígenes
ES2560902A2 (es) Método para la determinación de la intensidad de la modificación de la potencia de un medicamento
EP3053601A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER WITH CYB5R3 GENE OR PROTEIN AS AN ACTIVE SUBSTANCE
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
IL271224A (en) Aminoglycoside derivatives and uses thereof in treating genetic disorders
Sanford et al. Data, data, on the server: challenges in applying data analysis to operating room management
UA116011C2 (uk) Частинки фенілефрину резинату та їх використання у фармацевтичних композиціях
TH169543A (th) สารประกอบต้านแบคทีเรีย (Antibacterial Compounds)
Sboner et al. Identifying an ERG-positive subclass with clinical progression using expression profiling
TH153174A (th) สารประกอบอิมมิดาโซไพรโรลิดิโนน
ES2535453A1 (es) Composición de corcho y aplicaciones de la misma.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20170516